Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Clinical trial NCT02672475 · COMPLETED

Trial details

NCT number: NCT02672475
Sponsor: Vanderbilt-Ingram Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma

Start date: 2016-03-01
Primary completion: 2021-04-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.